Showing 4961-4970 of 5623 results for "".
- Sight Sciences Announces $30 Million Financinghttps://modernod.com/news/sight-sciences-announces-30-million-financing/2477405/Sight Sciences announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to support commercial expansion for Sight Sciences’ OMN
- Ribomic Enters License Agreement with AJU Pharma for RBM-007 in AMDhttps://modernod.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-amd/2477400/Ribomic announced that it has signed a license agreement with Korean pharmaceutical company AJU Pharm Co. for RBM-007 for the indication of the exudative age-related macular degeneration (AMD) in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Mala
- AAO Provides Updated COVID-19 Guidance for Outpatient Clinics and Elective Surgeryhttps://modernod.com/news/aao-provides-updated-guidance-for-outpatient-clinics-and-elective-surgery/2477395/In response to the state of national emergency declared at the federal level, particularly as COVID-19 progresses in a given community, ophthalmologists should seriously consider both the intensity of clinic scheduling and the issue of elective surgeries, particularly in elderly patients and thos
- AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsiahttps://modernod.com/news/agtc-announces-completion-of-enrollment-in-all-adult-dose-groups-of-its-ongoing-phase-1-2-clinical-trials-in-patients-with-achromatopsia/2477389/Applied Genetic Technologies Corporation (AGTC) announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its phase 1/2 clinical programs with achromatopsia due to mutation in the
- The Vision Council Examines Consumers’ Attitudes About COVID-19 in a Survey for Its Membershttps://modernod.com/news/the-vision-council-examines-consumers-attitudes-about-covid-19-in-a-survey-for-its-members/2477382/The Vision Council released a new COVID-19 Optical Impact consumer survey. Conducted by The Vision Council’s research team in February, the study surveyed more than 10,000 adults across the U.S. and was designed to measure respondents’ level of concern over exposure to COVID-19, including measure
- ARVO Annual Meeting Cancelledhttps://modernod.com/news/arvo-annual-meeting-cancelled/2477380/Due to the COVID-19 outbreak, the Board of Trustees at The Association for Research in Vision and Ophthalmology (ARVO) has decided to cancel its annual meeting, scheduled to take place May 1–7 in Baltimore. The ARVO organizers released an emailed statement to its membership outlining the d
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- Acuity Eye Group Offers Tips During National Nutrition Month For Better Visionhttps://modernod.com/news/acuity-eye-group-offers-tips-during-national-nutrition-month-for-better-vision/2477373/More and more evidence is showing that diet has an impact on every aspect of ones health, including vision. In honor of National Nutrition Month, doctors at Acuity Eye Group have tips and recommendations to eat your way to better vision. Research shows that a healthy diet and lifestyle wit
- Nicox Updates on Zerviate Progress in China and Expands the Countries of its Agreement with Ocumension Therapeuticshttps://modernod.com/news/nicox-updates-on-zerviate-progress-in-china-and-expands-the-countries-of-its-agreement-with-ocumension-therapeutics/2477370/Nicox SA announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in
- AAD Annual Meeting Becomes Latest Casualty of COVID-19 Outbreakhttps://modernod.com/news/aad-annual-meeting-becomes-latest-casualty-of-covid-19-outbreak/2477371/The American Academy of Dermatology (AAD) annual meeting became the latest casualty of the COVID-19 outbreak, with the conference cancelled on Tuesday. The meeting was scheduled to be held from March 20 to 24